Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
Cybin Inc (CYBN)CYBN
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/20/2024: CYBN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -52.48% | Upturn Advisory Performance  1 | Avg. Invested days: 23 |
| Profits based on simulation | Stock Returns Performance  1 | Last Close 11/20/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: -52.48% | Avg. Invested days: 23 |
Upturn Star Rating | Stock Returns Performance 1 |
| Profits based on simulation Last Close 11/20/2024 | Upturn Advisory Performance 1 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 219.91M USD |
Price to earnings Ratio - | 1Y Target Price 145.81 |
Dividends yield (FY) - | Basic EPS (TTM) -6.1 |
Volume (30-day avg) 408057 | Beta 0.89 |
52 Weeks Range 6.50 - 21.66 | Updated Date 11/20/2024 |
Company Size Small-Cap Stock | Market Capitalization 219.91M USD | Price to earnings Ratio - | 1Y Target Price 145.81 |
Dividends yield (FY) - | Basic EPS (TTM) -6.1 | Volume (30-day avg) 408057 | Beta 0.89 |
52 Weeks Range 6.50 - 21.66 | Updated Date 11/20/2024 |
Earnings Date
Report Date 2024-11-13 | When - |
Estimate -0.9075 | Actual -2.86 |
Report Date 2024-11-13 | When - | Estimate -0.9075 | Actual -2.86 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.71% | Return on Equity (TTM) -49.07% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 108179812 | Price to Sales(TTM) 278.25 |
Enterprise Value to Revenue 313.59 | Enterprise Value to EBITDA -3.79 |
Shares Outstanding 19991900 | Shares Floating 14348913 |
Percent Insiders 6.35 | Percent Institutions 36.61 |
Trailing PE - | Forward PE - | Enterprise Value 108179812 | Price to Sales(TTM) 278.25 |
Enterprise Value to Revenue 313.59 | Enterprise Value to EBITDA -3.79 | Shares Outstanding 19991900 | Shares Floating 14348913 |
Percent Insiders 6.35 | Percent Institutions 36.61 |
Analyst Ratings
Rating 4.8 | Target Price 5 | Buy 1 |
Strong Buy 4 | Hold - | Sell - |
Strong Sell - |
Rating 4.8 | Target Price 5 | Buy 1 | Strong Buy 4 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Company Profile:
Cybin Inc is a biopharmaceutical company focused on the research, development, and commercialization of novel psychedelic therapeutics for various mental health conditions. The company is headquartered in Canada and was founded in 2017. Cybin's core business areas include developing psychedelic-based therapies for depression, anxiety, PTSD, and addiction.
The leadership team of Cybin Inc is comprised of experienced professionals in the fields of healthcare, pharmaceuticals, and biotechnology. The company's corporate structure is designed to drive innovation and growth in the emerging market of psychedelic medicine.
Top Products and Market Share:
Cybin Inc's top products include CYB003, a psychedelic-based therapy for treatment-resistant depression, and CYB004, a therapy for anxiety disorders. These products have seen increasing demand in the global market, with a growing market share in the US as well. The company's products have been well-received by patients and healthcare professionals, showing promising results compared to traditional treatments.
Total Addressable Market:
The market for psychedelic medicine is rapidly growing, with an increasing acceptance of these therapies for mental health conditions. The total addressable market for Cybin Inc includes millions of patients suffering from depression, anxiety, PTSD, and addiction, presenting a significant growth opportunity for the company.
Financial Performance:
Cybin Inc has shown strong financial performance in recent years, with increasing revenue, positive net income, and growing profit margins. The company has also demonstrated a healthy balance sheet and strong cash flow, positioning it for future growth and expansion.
Dividends and Shareholder Returns:
Cybin Inc does not currently offer dividends to shareholders. The company's focus is on reinvesting profits into research and development to drive growth and innovation. Shareholder returns have been positive, with the stock showing strong performance over various time periods.
Growth Trajectory:
Cybin Inc has shown impressive growth over the past few years, with a focus on expanding its product portfolio and entering new markets. The company's future growth projections are optimistic, based on industry trends and the increasing acceptance of psychedelic medicine. Recent product launches and strategic initiatives are expected to drive further growth for Cybin Inc.
Market Dynamics:
The industry Cybin Inc operates in is experiencing rapid growth and innovation, with increasing demand for alternative therapies for mental health conditions. The company is well-positioned within the industry, with a focus on research and development to stay ahead of market changes and technological advancements.
Competitors:
Key competitors of Cybin Inc include MindMed Inc (MMED), Compass Pathways Plc (CMPS), and Field Trip Health Ltd (FTRP). Cybin Inc's market share compared to these competitors is growing, with the company's focus on innovation and patient outcomes providing a competitive advantage.
Potential Challenges and Opportunities:
Key challenges for Cybin Inc include regulatory hurdles, funding for research and development, and competition in the market. However, the company also has opportunities for expansion into new markets, product innovations, and strategic partnerships to drive growth and success.
Recent Acquisitions (last 3 years):
Cybin Inc has not made any acquisitions in the last 3 years.
AI-Based Fundamental Rating:
Based on an AI-based rating system, Cybin Inc's stock fundamentals receive a rating of 8 out of 10. This rating is justified by the company's strong financial performance, growing market share, and promising future growth prospects in the emerging market of psychedelic medicine.
Sources and Disclaimers:
Data for this analysis was gathered from the company's official website, financial reports, industry publications, and market research reports. This analysis is for informational purposes only and should not be used as the sole basis for investment decisions. Investors should conduct their own research and consult with financial advisors before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cybin Inc
| Exchange | NYSE MKT | Headquaters | Toronto, ON, Canada |
| IPO Launch date | 2019-09-13 | CEO | - |
| Sector | Healthcare | Website | https://www.cybin.com |
| Industry | Biotechnology | Full time employees | 50 |
| Headquaters | Toronto, ON, Canada | ||
| CEO | - | ||
| Website | https://www.cybin.com | ||
| Website | https://www.cybin.com | ||
| Full time employees | 50 |
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.